Aurinia to Participate in Late Breaking Oral Presentations at Two Upcoming Scientific Conferences
May 30 2017 - 4:19PM
Business Wire
Data to be presented at the 54th European Renal
Association-European Dialysis and Transplant Association Congress
and the Annual European Congress of Rheumatology (EULAR) 2017
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP), a clinical
stage biopharmaceutical company focused on the global immunology
market, today announced that is has been selected to present late
breaking oral presentations at both the 54th European Renal
Association-European Dialysis and Transplant Association’s
(ERA-EDTA) Congress and the Annual European Congress of
Rheumatology (EULAR) 2017, on June 3th-6th, 2017, Madrid, Spain and
June 14-17, Madrid, Spain, respectively.
“The selection of the 48-week data from our successful AURA-LV
Phase 2 study for two late-breaking oral presentations during these
key medical meetings underscores the high impact of the results to
the broader physician community, said Neil Solomons, M.D.,
Aurinia’s Chief Medical Officer. “We look forward to sharing our
findings and highlighting the importance of developing a potential
therapy for active lupus nephritis.”
Below is the schedule for the oral presentations:
54th European Renal Association-European
Dialysis and Transplant Association’s (ERA-EDTA)
CongressDate: Sunday, June 4, 2017Time: 11:45
a.m. GMTLocation: FEMA Feria de Madrid (North Congress
Center)Title: Steroid-Sparing Efficacy of Voclosporin in
Active Lupus Nephritis: Stable Kidney Function and BP Without
Electrolyte Complications at 48 Weeks
Annual European Congress of Rheumatology (EULAR)
2017Date: Friday, June 16, 2017Poster Presentation
Time: 11:20 a.m. GMTLocation: Hall 7BTitle: 48
Week Complete Remission of Active Lupus Nephritis With
Voclosporin
Editor’s Note: James Tumlin, M.D., study investigator for
Aurinia, will be participating in a press briefing at the 54th
ERA-EDTA Congress on Sunday, June 4, 2017 at 9:30 a.m. to present
the study, “Steroid-Sparing Efficacy of Voclosporin in Active Lupus
Nephritis: Stable Kidney Function and BP Without Electrolyte
Complications at 48 Weeks”. He will be presenting the study in FEMA
Feria de Madrid (North Congress Center), Room N112.
About AuriniaAurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering
from serious diseases with a high unmet medical need. The Company
is currently developing voclosporin, an investigational drug, for
the treatment of lupus nephritis (LN), in an inflammation of the
kidney caused by Systemic Lupus Erythematosus (SLE) and represents
a serious progression of SLE. The Company is headquartered in
Victoria, BC and focuses its development efforts globally.
Visit www.auriniapharma.com for more information.
Forward Looking StatementsThis press release contains
forward-looking statements, including statements related to
Aurinia's analysis, assessment, conclusions and impact of the
results of the AURA-LV clinical study, and the efficacy and safety
of voclosporin. It is possible that such results or conclusions may
change based on further analyses of these data. Words such as
"plans," "intends," “may,” "will," "believe," and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Aurinia’s current
expectations. Forward-looking statements involve risks and
uncertainties. Aurinia’s actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the risk that
Aurinia’s analyses, assessment and conclusions of the results of
the AURA-LV clinical study set forth in this release may change
based on further analyses of such data, and the risk that Aurinia’s
clinical studies for voclosporin may not lead to regulatory
approval. These and other risk factors are discussed under "Risk
Factors" and elsewhere in Aurinia’s Annual Information Form for the
year ended December 31, 2016 filed with Canadian securities
authorities and available at www.sedar.com and on Form 40-F with
the U.S. Securities Exchange Commission and available at
www.sec.gov, each as updated by subsequent filings, including
filings on Form 6-K. Aurinia expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Aurinia's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170530006319/en/
Aurinia Pharmaceuticals Inc.Investor Contact:Celia
EconomidesVP, Public Affairsceconomides@auriniapharma.comorMedia
Contact:Christopher Hippolyte,
212-364-0458Christopher.hippolyte@inventivhealth.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024